DBVT
DBV Technologies S.A.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S Jan 29 1 insider sell $2.6K at $4.86
- R Mar 26 DBV Technologies reported full-year 2025 financial results, showing…
- R Jul 27 DBV Technologies filed an automatic shelf registration statement (S-…
- S Jul 29 1 insider sell $1.3K at $2.70
- X Jul 31 Short interest jumps 25.7% to 1.85M
- E Aug 3 Trial readout: T-90d Trial Readout: Safety Study of Viaskin® Peanut Patch…
- R Sep 30 DBV Technologies submitted a Biologics License Application (BLA) to…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $3.8K.
- InstitutionsMIXED
Q2 2026: 7 added (0 new), 6 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.126 → −$0.146 over 90 days. 0 up, 1 down in 30 days.
- Short sellersCOVERING
Short interest −22.4% to 872.1K shares. 2.0 days to cover, ≈1.5% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Artisan Partners Limited Partnership | TRIM | $22.5M |
| UBS Group AG | DOUBLED | $21.5M |
| MORGAN STANLEY | DOUBLED | $15.7M |
| AMERIPRISE FINANCIAL INC | ADD | $6.2M |
| JANE STREET GROUP, LLC | DOUBLED | $3.7M |
| HRT FINANCIAL LP | DOUBLED | $2.5M |
| NEW YORK STATE COMMON RETIREMENT FUND | TRIM | $2.0M |
| Russell Investments Group, Ltd. | TRIM | $1.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jun 2026| Date | Firm | Rating |
|---|---|---|
| Jun 30, 2026 | Citizens MAINTAIN | Market Outperform |
| May 4, 2026 | Guggenheim REITERATE | Buy |
| May 1, 2026 | Citizens MAINTAIN | Market Outperform |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 29, 2026 | Mohideen Pharis Chief Medical Officer | SELL | $1.3K |
| Jan 29, 2026 | Mohideen Pharis Chief Medical Officer | SELL | $2.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.15 | -$0.23–-$0.10 | -0.5% | $581.6K |
| Next Q | -$0.15 | -$0.22–-$0.11 | -0.7% | $581.6K |
| Current FY | -$0.44 | -$0.64–-$0.31 | +4.5% | $3.6M |
| Next FY | -$0.43 | -$0.79–-$0.25 | +5.7% | $62.3M |
Short side
FINRA· Oct 15, 2026Washington
SecBot reports
5 filings · 2 press releases · 2 bullish · 1 bearish · 2 neutral- BULLISH 8-KSep 29, 2026
DBV Technologies submitted a Biologics License Application (BLA) to the FDA for the VIASKIN Peanut…
The FDA's acceptance of the BLA for Priority Review and the subsequent PDUFA date will be the next key catalysts. Monitor for FDA filing acceptance and any advisory committee meeting announcements…
- BEARISH S-3ASRJul 27, 2026
DBV Technologies filed an automatic shelf registration statement (S-3ASR) to offer up to $150…
Monitor daily volume and periodic disclosures of ADS sales under the ATM; actual dilution depends on the pace of sales. The filing overhang may pressure DBVT shares near-term.
- NEUTRAL PRESS-RELEASEJul 6, 2026
DBV Technologies published its semi-annual liquidity contract report with ODDO BHF, detailing…
This is a routine regulatory filing with no trading signal. Monitor upcoming clinical trial milestones for the VIASKIN Peanut Patch, which are the primary value drivers for DBVT.
- NEUTRAL 8-KJun 29, 2026
DBV Technologies announced that it is delaying the BLA submission for its VIASKIN Peanut Patch in…
The BLA delay to Q3 2026 is a modest negative — it pushes the potential approval and first-revenue timeline by at least one quarter, but the FDA has not requested additional data, which limits…
All DBVT filing & press-release reports (7)
- 8-K reportSep 29, 2026
- S-3ASR reportJul 27, 2026
- PRESS-RELEASE reportJul 6, 2026
- 8-K reportJun 29, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 26, 2026